A citation-based method for searching scientific literature

Sangjoon Choi, Sujin Park, Hyunjin Kim, So Young Kang, Soomin Ahn, Kyoung-Mee Kim. Biomedicines 2022
Times Cited: 2







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.
E Van Cutsem, C Boni, J Tabernero, B Massuti, G Middleton, F Dane, P Reichardt, F L Pimentel, A Cohn, P Follana,[...]. Ann Oncol 2015
95
50

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Eric Van Cutsem, Vladimir M Moiseyenko, Sergei Tjulandin, Alejandro Majlis, Manuel Constenla, Corrado Boni, Adriano Rodrigues, Miguel Fodor, Yee Chao, Edouard Voznyi,[...]. J Clin Oncol 2006
50

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Yelena Y Janjigian, Johanna Bendell, Emiliano Calvo, Joseph W Kim, Paolo A Ascierto, Padmanee Sharma, Patrick A Ott, Katriina Peltola, Dirk Jaeger, Jeffry Evans,[...]. J Clin Oncol 2018
311
50

FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort.
Marcello Maugeri-Saccà, Laura Pizzuti, Domenico Sergi, Maddalena Barba, Franca Belli, Silvia Fattoruso, Diana Giannarelli, Antonella Amodio, Sara Boggia, Patrizia Vici,[...]. J Exp Clin Cancer Res 2013
19
50

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Yelena Y Janjigian, Kohei Shitara, Markus Moehler, Marcelo Garrido, Pamela Salman, Lin Shen, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, Arinilda Campos Bragagnoli,[...]. Lancet 2021
307
50


Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
Ronan Flippot, Cécile Dalban, Brigitte Laguerre, Delphine Borchiellini, Gwénaelle Gravis, Sylvie Négrier, Christine Chevreau, Florence Joly, Lionnel Geoffrois, Sylvain Ladoire,[...]. J Clin Oncol 2019
86
50

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204).
Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, Christopher D Lao, Stergios J Moschos, Omid Hamid, Michael B Atkins, Karl Lewis, Reena P Thomas, John A Glaspy,[...]. Neuro Oncol 2021
23
50

Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer.
Jean-David Fumet, Nicolas Isambert, Alice Hervieu, Sylvie Zanetta, Jean-Florian Guion, Audrey Hennequin, Emilie Rederstorff, Aurélie Bertaut, Francois Ghiringhelli. ESMO Open 2018
32
50

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Hansjochen Wilke, Kei Muro, Eric Van Cutsem, Sang-Cheul Oh, György Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Oleg Lipatov, Tae-You Kim,[...]. Lancet Oncol 2014
50

Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.
Ronan J Kelly, Jeeyun Lee, Yung-Jue Bang, Khaldoun Almhanna, Mariela Blum-Murphy, Daniel V T Catenacci, Hyun Cheol Chung, Zev A Wainberg, Michael K Gibson, Keun-Wook Lee,[...]. Clin Cancer Res 2020
45
50


Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.
Hugo E R Ford, Andrea Marshall, John A Bridgewater, Tobias Janowitz, Fareeda Y Coxon, Jonathan Wadsley, Wasat Mansoor, David Fyfe, Srinivasan Madhusudan, Gary W Middleton,[...]. Lancet Oncol 2014
382
50

PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer.
Camille Evrard, Christophe Louvet, Farid El Hajbi, Frédéric DI Fiore, Karine LE Malicot, Thomas Aparicio, Olivier Bouché, Pierre Laurent-Puig, Frédéric Bibeau, Thierry Lecomte,[...]. Dig Liver Dis 2021
6
50

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Peter C Thuss-Patience, Albrecht Kretzschmar, Dmitry Bichev, Tillman Deist, Axel Hinke, Kirstin Breithaupt, Yasemin Dogan, Bernhard Gebauer, Guido Schumacher, Peter Reichardt. Eur J Cancer 2011
397
50

Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study).
Aziz Zaanan, Emmanuelle Samalin, Thomas Aparicio, Olivier Bouche, Pierre Laurent-Puig, Sylvain Manfredi, Pierre Michel, Carole Monterymard, Marie Moreau, Philippe Rougier,[...]. Dig Liver Dis 2018
9
50


Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
Charles S Fuchs, Jiri Tomasek, Cho Jae Yong, Filip Dumitru, Rodolfo Passalacqua, Chanchal Goswami, Howard Safran, Lucas Vieira Dos Santos, Giuseppe Aprile, David R Ferry,[...]. Lancet 2014
50

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.
Kohei Shitara, Eric Van Cutsem, Yung-Jue Bang, Charles Fuchs, Lucjan Wyrwicz, Keun-Wook Lee, Iveta Kudaba, Marcelo Garrido, Hyun Cheol Chung, Jeeyun Lee,[...]. JAMA Oncol 2020
256
50

Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.
Shuichi Hironaka, Shinya Ueda, Hirofumi Yasui, Tomohiro Nishina, Masahiro Tsuda, Takehiko Tsumura, Naotoshi Sugimoto, Hideki Shimodaira, Shinya Tokunaga, Toshikazu Moriwaki,[...]. J Clin Oncol 2013
309
50

Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08).
Yoshikazu Takahashi, Yu Sunakawa, Eisuke Inoue, Ryohei Kawabata, Atsushi Ishiguro, Yosuke Kito, Yusuke Akamaru, Masazumi Takahashi, Hiroshi Yabusaki, Jin Matsuyama,[...]. Gastric Cancer 2022
5
50

Neurological complications of cancer immunotherapy.
Patrick Roth, Sebastian Winklhofer, Antonia M S Müller, Reinhard Dummer, Maximilian J Mair, Dorothee Gramatzki, Emilie Le Rhun, Markus G Manz, Michael Weller, Matthias Preusser. Cancer Treat Rev 2021
15
50

DPP9: Comprehensive In Silico Analyses of Loss of Function Gene Variants and Associated Gene Expression Signatures in Human Hepatocellular Carcinoma.
Jiali Carrie Huang, Abdullah Al Emran, Justine Moreno Endaya, Geoffrey W McCaughan, Mark D Gorrell, Hui Emma Zhang. Cancers (Basel) 2021
7
50

Quantifying heterogeneity in a meta-analysis.
Julian P T Higgins, Simon G Thompson. Stat Med 2002
50

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
50

Identification of Potential Biomarkers and Survival Analysis for Head and Neck Squamous Cell Carcinoma Using Bioinformatics Strategy: A Study Based on TCGA and GEO Datasets.
Yujie Shen, Jinhui Liu, Liqing Zhang, Shikun Dong, Jiacheng Zhang, Yaqin Liu, Han Zhou, Weida Dong. Biomed Res Int 2019
23
50

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.
Robert D Schreiber, Lloyd J Old, Mark J Smyth. Science 2011
50

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
James G Christensen, Helen Y Zou, Maria E Arango, Qiuhua Li, Joseph H Lee, Scott R McDonnell, Shinji Yamazaki, Gordon R Alton, Barbara Mroczkowski, Gerrit Los. Mol Cancer Ther 2007
501
50

TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells.
Taiwen Li, Jingyu Fan, Binbin Wang, Nicole Traugh, Qianming Chen, Jun S Liu, Bo Li, X Shirley Liu. Cancer Res 2017
50

Antiproliferative activity of kinetin riboside on HCT-15 colon cancer cell line.
Mehdi Rajabi, Elena Gorincioi, Enzo Santaniello. Nucleosides Nucleotides Nucleic Acids 2012
8
50

Nomograms in oncology: more than meets the eye.
Vinod P Balachandran, Mithat Gonen, J Joshua Smith, Ronald P DeMatteo. Lancet Oncol 2015
50


Upregulated INHBA expression is associated with poor survival in gastric cancer.
Quan Wang, Yu-Gang Wen, Da-Peng Li, Jun Xia, Chong-Zhi Zhou, Dong-Wang Yan, Hua-Mei Tang, Zhi-Hai Peng. Med Oncol 2012
174
50


Infiltration of dendritic cells into regional lymph nodes in gastric cancer.
S Tsujitani, A Oka, A Kondo, M Ikeguchi, M Maeta, N Kaibara. Cancer 1995
16
50

Tumor-Associated Macrophages and Inflammatory Microenvironment in Gastric Cancer: Novel Translational Implications.
Karim Rihawi, Angela Dalia Ricci, Alessandro Rizzo, Stefano Brocchi, Giovanni Marasco, Luigi Vincenzo Pastore, Fabiola Lorena Rojas Llimpe, Rita Golfieri, Matteo Renzulli. Int J Mol Sci 2021
30
50

Comparative studies of adriamycin and 28-deacetyl sendanin on in vitro growth inhibition of human cancer cell lines.
H M Kim, G T Oh, S B Han, D H Hong, B Y Hwang, Y H Kim, J J Lee. Arch Pharm Res 1994
12
50

CTHRC1 is upregulated by promoter demethylation and transforming growth factor-β1 and may be associated with metastasis in human gastric cancer.
Ping Wang, Ying-Chao Wang, Xiao-Yu Chen, Zhi-Yong Shen, Hui Cao, Yan-Jie Zhang, Jian Yu, Jing-De Zhu, You-Yong Lu, Jing-Yuan Fang. Cancer Sci 2012
65
50

The Role of CTHRC1 in Regulation of Multiple Signaling and Tumor Progression and Metastasis.
Dan Mei, Yue Zhu, Lingling Zhang, Wei Wei. Mediators Inflamm 2020
23
50

A narrative review of individualized treatments of genitourinary tumors: is the future brighter with molecular evaluations?
Francesca Giunchi, Tania Franceschini, Michelangelo Fiorentino. Transl Androl Urol 2021
4
50

Overexpression of HS6ST2 is associated with poor prognosis in patients with gastric cancer.
Yi Jin, Jun He, Jing Du, Ru-Xuan Zhang, Hai-Bo Yao, Qin-Shu Shao. Oncol Lett 2017
17
50

The Human Protein Atlas as a proteomic resource for biomarker discovery.
F Pontén, J M Schwenk, A Asplund, P-H D Edqvist. J Intern Med 2011
153
50

A basic introduction to fixed-effect and random-effects models for meta-analysis.
Michael Borenstein, Larry V Hedges, Julian P T Higgins, Hannah R Rothstein. Res Synth Methods 2010
50

Progress of Gastric Cancer Surgery in the era of Precision Medicine.
Yumin Wang, Luyuan Zhang, Yi Yang, Shan Lu, Hao Chen. Int J Biol Sci 2021
4
50

Identifying the hub gene in gastric cancer by bioinformatics analysis and in vitro experiments.
Feiran Wang, Qiang Xue, Dong Xu, Yasu Jiang, Chong Tang, Xianchen Liu. Cell Cycle 2020
10
50

PCOLCE Is Potent Prognostic Biomarker and Associates With Immune Infiltration in Gastric Cancer.
Aizhai Xiang, Xia Lin, Lvping Xu, Honggang Chen, Jufeng Guo, Fang Zhou. Front Mol Biosci 2020
3
50

RNAactDrug: a comprehensive database of RNAs associated with drug sensitivity from multi-omics data.
Qun Dong, Feng Li, Yanjun Xu, Jing Xiao, Yingqi Xu, Desi Shang, Chunlong Zhang, Haixiu Yang, Zihan Tian, Kai Mi,[...]. Brief Bioinform 2020
9
50


Effects of kinetin riboside on proliferation and proapoptotic activities in human normal and cancer cell lines.
Paulina Dudzik, Joanna Dulińska-Litewka, Eliza Wyszko, Patrycja Jędrychowska, Maciej Opałka, Jan Barciszewski, Piotr Laidler. J Cell Biochem 2011
11
50



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.